FY2024 EPS Estimates for TSE:BHC Boosted by Analyst

Bausch Health Companies Inc. (TSE:BHC) – Equities researchers at Zacks Research increased their FY2024 earnings per share estimates for shares of Bausch Health Companies in a report released on Tuesday, October 22nd. Zacks Research analyst R. Department now forecasts that the company will earn $4.98 per share for the year, up from their prior estimate of $4.88. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2024 earnings at $1.50 EPS, Q1 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.56 EPS, Q4 2025 earnings at $1.73 EPS, FY2025 earnings at $5.77 EPS, Q1 2026 earnings at $1.50 EPS and Q2 2026 earnings at $1.50 EPS.

A number of other equities research analysts have also issued reports on the company. Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Raymond James upgraded Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 10th.

Bausch Health Companies Trading Down 0.3 %

Shares of BHC stock opened at C$11.18 on Thursday. Bausch Health Companies has a 52-week low of C$5.45 and a 52-week high of C$15.43. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19. The firm has a market capitalization of C$4.10 billion, a PE ratio of -6.39, a PEG ratio of 0.21 and a beta of 0.77. The stock has a fifty day simple moving average of C$9.50 and a two-hundred day simple moving average of C$9.95.

Bausch Health Companies (TSE:BHC) last issued its quarterly earnings results on Thursday, August 1st. The company reported C$1.22 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C$1.22. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The business had revenue of C$3.29 billion during the quarter, compared to analyst estimates of C$3.20 billion.

Insider Activity

In other news, Senior Officer Seana Lynne Carson sold 13,370 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. Company insiders own 11.28% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.